Skip to main content
SpringerLink
Log in

Urothelial Carcinoma of the Lower Urinary Tract: Introduction

  • Chapter
Imaging in Oncological Urology

  • 1347 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ali-el-Dein B, Nabeeh A, Ismail EH, Ghoneim MA. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol. 1999;162:339–42.

    Article  PubMed  CAS  Google Scholar 

  2. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987;5:441–9.

    PubMed  CAS  Google Scholar 

  3. Boffetta P, Silverman DT. A meta-analysis of bladder cancer and diesel exhaust exposure. Epidemiology. 2001;12(1):125–30.

    Article  PubMed  CAS  Google Scholar 

  4. Carmack AJK, Soloway MS. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology. 2006;67(3 Suppl 1):3–8; discussion 8–10.

    Article  PubMed  Google Scholar 

  5. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490–3.

    Article  PubMed  CAS  Google Scholar 

  6. Ende N, Woods LP, Shelley HS. Carcinoma originating in ducts surrounding the prostatic urethra. Amer J Clin Pathol. 1963;40:183.

    CAS  Google Scholar 

  7. Ferlay, Bray, Pisani, Parkin. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. Lyon: IARC Press; 2001.

    Google Scholar 

  8. Fitzpatrick JM, West AB, Butler MR, Lane V, O’Flynn JD. Superficial bladder tumors (stage pTa grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986;135:920–2.

    PubMed  CAS  Google Scholar 

  9. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PMM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003;169:1975–82.

    Google Scholar 

  10. Guo Z, Linn JF, Wu G, Anzick SL, Eisenberger CF, Halachmi S, et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med. 2004;10(4):374–81.

    Article  PubMed  CAS  Google Scholar 

  11. Hautmann RE, de Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol. 1999;161:422–7.

    Article  PubMed  CAS  Google Scholar 

  12. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083–6.

    PubMed  CAS  Google Scholar 

  13. Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996;156(4):1286–7.

    Article  PubMed  CAS  Google Scholar 

  14. Herr HW. Does cystoscopy correlate with the histology of recurrent papillary tumors of the bladder? BJU Int. 2001;88:683–5.

    Article  PubMed  CAS  Google Scholar 

  15. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–6.

    Article  PubMed  CAS  Google Scholar 

  16. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol. 1999;162(1):74–6.

    Article  PubMed  CAS  Google Scholar 

  17. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immuno-histochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165:1124–30.

    Article  PubMed  CAS  Google Scholar 

  18. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. Long-term follow-up of a bladder carcinoma cohort: routine follow up urography is not necessary. J Urol. 1998;160:45–8.

    Article  PubMed  Google Scholar 

  19. Jakse G, Algaba F, Malmstrom P-U, Oosterlinck WA. Second-look TUR in T1 transitional cell carcinoma: Why? Eur Urol. 2001;45:539–46.

    Article  Google Scholar 

  20. Jakse G, Hall R, Bono A, Hoeltl W, Carpentier P, Spaander JP, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group hase II protocol 30861. Eur Urol. 2001;40:144–50.

    Article  PubMed  CAS  Google Scholar 

  21. Jewett MAS, Nieder AM. T1 Urothelial carcinoma of bladder. Bladder tumors. 2006;1:189–218.

    Google Scholar 

  22. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42:167–74.

    Article  PubMed  Google Scholar 

  23. Kirk D, Hinton CE, Shaldon C. Transitional cell carcinoma of the prostate. Br J Urol. 1979;51:575–8.

    Article  PubMed  CAS  Google Scholar 

  24. Kirkali ZCT, Manhoharan M. Bladder cancer, epidemiology, staging, grading, and diagnosis. 2006;1:13–64.

    Google Scholar 

  25. Kolozsky Z. Histopathological “self control” in transurethral resection of bladder tumors. Br J Urol. 1991;67:162–4.

    Article  Google Scholar 

  26. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165:600–11.

    Article  PubMed  CAS  Google Scholar 

  27. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000;6:2618–25.

    PubMed  CAS  Google Scholar 

  28. Koya MP, Simon MA, et al. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004–10.

    Article  PubMed  Google Scholar 

  29. Lamm DL, Herr HW, Jakse G, Kuroda M, Mostofi FK, Okajima E, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol. 1998;4:130–138.

    Article  Google Scholar 

  30. Lamm DL. BCG immunotherapy for transitional cell carcinoma of the bladder Oncol. 1995;9:947–52.

    CAS  Google Scholar 

  31. Lamm DL. Carcinoma in situ. Urol Clin N Am. 1992;19:499–508.

    CAS  Google Scholar 

  32. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group Study. Urol Oncol. 1995;1:119–26.

    Google Scholar 

  33. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, et al. A randomized trial of intravesical doxorubicin and immunotherapy with BCG for transitional cell carcinoma of the bladder. N Engl J Med. 1991;325:1205–9.

    PubMed  CAS  Google Scholar 

  34. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, ottesman JE, Lowe BA, et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and CIS transitional cell carcinoma of the bladder: a randomized SWOG study. J Urol. 2000;163:1124–9.

    Article  PubMed  CAS  Google Scholar 

  35. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000;27:1–13, vii.

    Article  PubMed  CAS  Google Scholar 

  36. Lokeshwar VB. Cytology and tumor markers. Bladder Tumors. 2006;1:65–138.

    Google Scholar 

  37. Lokeshwar VB. Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? [Miscellaneous]. J Urol. 2001;165(4):1067–77.

    Article  PubMed  CAS  Google Scholar 

  38. Lokeshwar VB, Soloway MS. Re: urine based markers of urological malignancy. J Urol. 2002;167(3):1406.

    Article  PubMed  Google Scholar 

  39. Lokeshwar VB, Obek CAN, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol. 2000;163(1):348.

    Article  PubMed  CAS  Google Scholar 

  40. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology. 2003;35(6):484–91.

    Article  PubMed  Google Scholar 

  41. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109–18.

    Article  PubMed  Google Scholar 

  42. Malkowicz SB. Muscle invasive urothelial carcinoma of bladder. Bladder Tumors. 2006;1:p. 219–38.

    Google Scholar 

  43. Manoharan M, Soloway MS. Optimal management of the T1G3 bladder cancer. Urol Clin North Am. 2005;32(2):133–45.

    Article  PubMed  Google Scholar 

  44. Manoharan, Murugesan SM. Superficial transitional cell carcinoma of the bladder: management and prognosis. Urol oncol. 2005.

    Google Scholar 

  45. Marcus PM, Vineis P, et al. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000;10(2):115–22.

    Article  PubMed  CAS  Google Scholar 

  46. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debré B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003;43:241–5.

    Article  PubMed  Google Scholar 

  47. Mohr DN, Offord KP, Owen RA, Melton J III. Asymptomatic microhematuria and urologic disease. A population-based study. JAMA. 1986;256:224–9.

    Article  PubMed  CAS  Google Scholar 

  48. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005;13(2):143–53.

    Article  PubMed  Google Scholar 

  49. Nieder AM. Soloway MS. Eliminate the term “superficial” bladder cancer. J Urol. 2006;175(2):417–8.

    Article  PubMed  Google Scholar 

  50. Nieder AM, Meinbach DS, et al. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol. 2005;174(6):2307–9.

    Article  PubMed  Google Scholar 

  51. Nieder AM, Meinbach DS, et al. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol. 2005;174(6):2307–9.

    Article  PubMed  Google Scholar 

  52. Oosterlinck W, Kurth K, Schröder F, Bultinck J, Hammond B, Sylvester R, et al. A prospective EORTC-GU group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993;149:749–52.

    PubMed  CAS  Google Scholar 

  53. Oosterlinck W, Kurth K, Schroder F, Sylvester R. A plea for cold biopsy, fulguration and immediate bladder instillation with Epirubicin in small superficial bladder tumors. Eur Urol. 1993;23:457–9.

    PubMed  CAS  Google Scholar 

  54. Oosterlinck W, Lobel B, Jakse G, Malmstrom P, Stockle M, Sternberg C. The EAU working group on oncological urology. Guidelines on bladder cancer. Eur Urol. 2002;41:105–12.

    Article  PubMed  Google Scholar 

  55. Oosterlinck WSE. Low grade Ta, (noninvasive) urothelial carcinoma. Bladder Tumors. 2006;1:139–64.

    Google Scholar 

  56. Pagano F, Bassi PF, Ferranti GL, Piazza N, Abantagelo G, Pappagallo GL, et al. Is stage pT4a (D1) reliable assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol. 1996;155:244–7.

    Article  PubMed  CAS  Google Scholar 

  57. Posey JT, Soloway MS, et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res. 2003;63(10):2638–44.

    PubMed  CAS  Google Scholar 

  58. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for apical sparing surgery. J Urol. 2004;171:646–51.

    Article  PubMed  Google Scholar 

  59. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, lfthan O, et al. Alternating mitomycin and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol. 1995;154:2050–3.

    Article  PubMed  CAS  Google Scholar 

  60. Sadek S, Soloway MS, et al. (1999). The value of upper tract cytology after transurethral resection of bladder tumor in patients with bladder transitional cell cancer. J Urol. 1999;161(1):77–9.

    Article  PubMed  CAS  Google Scholar 

  61. Sarosdy MF, deVere White RW, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol. 1995;154(2):379–83.

    Article  PubMed  CAS  Google Scholar 

  62. Schellhammer PF, Bean MA, Whitmore WFJ. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol. 1997;118:399–403.

    Google Scholar 

  63. Scher HI, Motzer RJ. Bladder and Renal Cell Carcinomas. Harrison’s Principles of Internal Medicine.

    Google Scholar 

  64. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and T1 Bladder Cancer (Cochrane review). The Cochrane Library, Issue 4, 2003.

    Google Scholar 

  65. Simon MA, Lokeshwar VB, et al. Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol. 2003;47(2): 91–107.

    Article  PubMed  Google Scholar 

  66. Single dose v ersus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumors: a prospective randomized controlled study. Br J Urol. 1997;79:731–5.

    Google Scholar 

  67. Soloway MS. Editorial comments: apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 1995;153(5):1450.

    Article  Google Scholar 

  68. Soloway MS. Bladder tumor markers, intravesical therapy and systemic chemotherapy. J Urol. 2001;166(2):488–9.

    Article  PubMed  CAS  Google Scholar 

  69. Soloway MS. Editorial: bladder Cancer. How can we make a difference? [Editorial]. J Urol. 2003;170(5):1781–2.

    Article  PubMed  Google Scholar 

  70. Soloway MS. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol. 2006;24(1):58–61.

    PubMed  Google Scholar 

  71. Soloway MS, Bruck DS, et al. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170(2, Part 1):438–41.

    Article  PubMed  Google Scholar 

  72. Soloway MS, Sofer M, et al. Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The Bladder. J Urol. 2002;167(4):1573–83.

    Article  PubMed  Google Scholar 

  73. Solsona E, Iborra I, Ricos J, Monros J, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and longterm follow up. J Urol. 1999;161:1120–3.

    Article  PubMed  CAS  Google Scholar 

  74. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 1997;3:621–4.

    Article  PubMed  CAS  Google Scholar 

  75. Sylvester RJ, van der Meijden A, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168: 1964–70.

    Article  PubMed  CAS  Google Scholar 

  76. Sylvester R, van der Meijden A. High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. 2006;1:165–88.

    Google Scholar 

  77. Taguchi I, Gohji K, Hara I, Gotoh A, Yamada Y, Yamanaka K, et al. Clinical evaluation of random biopsy of urinary bladder in patients with superficial bladder cancer. Int J Urol. 1998;5(1): 30–4.

    Article  PubMed  CAS  Google Scholar 

  78. Vaidya A, Soloway MS, et al. De novo muscle invasive bladder cancer: is there a change in trend? [Article]. J Urol. 2001;165(1): 47–50.

    Article  PubMed  CAS  Google Scholar 

  79. Van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol. 1999;35(4):267–71.

    Article  PubMed  Google Scholar 

  80. Yousem DM, Gatewood OM, Goldman SM, Marshall FF. Synchronous and metachronous transitional cell carcinoma of the urinary tract: prevalence, incidence, and radiographic detection. Radiology. 1988;167:613–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neobladder and bladder Cancer Center Department of Urology, University of Miami School of Medicine, 016960 (M814), Miami, FL 33101, USA

    M. Manoharan

Authors
  1. M. Manoharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Ayyathurai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M.S. Soloway
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Academic Medical Center, Amsterdam, The Netherlands

    Jean J.M.C.H. de la Rosette  & Hessel Wijkstra  & 

  2. Department of Urology, The George Washington University, Washington, USA

    Michael J. Manyak

  3. Department of Radiology, Massachusetts General Hospital, Boston, DC, USA

    Mukesh G. Harisinghani

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Manoharan, M., Ayyathurai, R., Soloway, M. (2009). Urothelial Carcinoma of the Lower Urinary Tract: Introduction. In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-759-6_15

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-514-1

  • Online ISBN: 978-1-84628-759-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation